Computer software assurance (CSA) is now FDA's recommended framework for validating production and quality system software, replacing the documentation-heavy computer system validation (CSV) model that has governed regulated labs for decades. Finalized in September 2025 and updated February 2026, the CSA guidance matters specifically for labs implementing AI: its risk-based structure suits the update cadence and behavioral complexity of AI systems far better than the checkpoint-driven approach CSV was built around.
Quick Take:
- Computer system validation (CSV) required exhaustive documentation and scripted testing for all software regardless of risk; computer software assurance (CSA) scales effort to actual risk
- FDA's CSA guidance was originally finalized September 24, 2025 and updated February 3, 2026; it explicitly states that CSA principles apply to AI tools used in production or quality systems
- CSA does not remove validation requirements; it changes the emphasis from generating documentation to demonstrating reasoned, risk-proportionate confidence
- The four-step CSA process: define intended use, assess risk of failure, plan proportionate assurance activities, document the basis for confidence
- AI systems benefit from CSA because risk-based, lifecycle-oriented assurance accommodates model updates and changing outputs in ways CSV cannot
What computer system validation required
Computer system validation (CSV) emerged in the 1990s as regulated industries moved from paper-based records to computerized systems. It codified a rigorous, linear process: installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ), each producing formal documented evidence that a system was installed correctly, functioned as specified, and performed reliably under real conditions.
CSV provided genuine assurance when software was largely custom-built, changed infrequently, and operated in tightly controlled on-premise environments. The problem was that the model scaled with documentation volume rather than risk. A low-risk scheduling tool received the same validation overhead as a high-risk batch release system.
The GxP validation obligations that underpin all regulated software requirements remained constant; what changed is how industry understood the most efficient way to meet them.
Traditional CSV requires that when any change is made to software, the validation status must be re-established with a fresh impact analysis and regression testing. In a modern software environment, particularly for AI systems retrained or updated on a rolling basis, this creates a compliance burden disproportionate to the actual risk involved.
What computer software assurance introduces
Computer software assurance, as defined in FDA's guidance originally finalized September 2025 and updated February 2026, is a risk-based approach to establishing and maintaining confidence that software is fit for its intended use. CSA starts with the question "if this software fails, what is the worst outcome for product quality or patient safety?" and uses the answer to determine how much assurance effort is appropriate.
The computer software assurance framework follows four steps: define the intended use of the software within the production or quality system; assess the risk of failure, specifically the consequences for product quality, patient safety, and data integrity; plan assurance activities proportionate to that risk; and document the basis for confidence rather than every test artifact. This last shift is the most significant departure from CSV practice.
Advanced Lab Management Certificate
The Advanced Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
CSA does not eliminate documentation, testing, or lifecycle controls. Labs retain the obligation to demonstrate that regulated software performs as intended. What changes under computer software assurance is the flexibility to demonstrate it in ways calibrated to actual risk, including exploratory testing for low-risk functions and credited vendor evidence in place of internally recreated validation packages.
Key differences that matter in practice
| Dimension | CSV | Computer software assurance |
|---|---|---|
| Starting point | System features and test scripts | Intended use and risk of failure |
| Testing scope | Comprehensive scripted testing of all functions | Risk-scaled; exploratory testing permitted for low-risk functions |
| Documentation | Extensive IQ/OQ/PQ protocols and reports | Objective evidence sufficient to demonstrate confidence |
| Software updates | Revalidation triggered by any change | Risk assessment determines whether assurance activities are needed |
| Vendor evidence | Typically recreated internally | Supplier testing and SDLC documentation can be credited |
| Cloud and SaaS | Difficult to accommodate | Explicitly addressed across SaaS, PaaS, and IaaS models |
For most lab systems, the practical shift under computer software assurance is that low-risk functions require substantially less testing effort, while high-risk functions retain rigorous assurance requirements. The total compliance burden decreases; the quality of thinking required increases. Inspectors increasingly look for rational justification grounded in risk assessment, not merely the volume of evidence produced.
How CSA applies to AI systems specifically
AI systems challenge CSV in three ways that computer software assurance handles better. The GxP validation and data integrity obligations that apply to all regulated lab software apply here too; CSA is the mechanism for meeting them efficiently.
Update frequency is the first. A machine learning model may be retrained on new data or have its inference logic adjusted without any change to the underlying code. Under CSV, any such change could trigger a full revalidation cycle.
Want to stay up to date on the latest lab management news?
Under computer software assurance, the lab performs a risk assessment of the update: does it affect a function with direct impact on regulated outputs? The answer determines the level of assurance activity required, allowing low-impact updates to proceed without the same documentation overhead that a high-risk change would demand.
Behavioral variability is the second. Traditional software produces deterministic outputs; AI systems produce probabilistic outputs that may vary with context. CSV test scripts built on fixed expected values map poorly to AI behavior.
Computer software assurance accommodates this by designing assurance activities around the risk the variability poses, rather than demanding a single predetermined output for every test case. This is a meaningful structural advantage for any lab deploying AI in quality-critical workflows.
Lifecycle continuity is the third. CSA emphasizes maintaining a validated state throughout the system's life cycle, including patches, upgrades, and SaaS updates. For AI systems requiring ongoing performance monitoring to detect model drift, this framing aligns the regulatory requirement with sound operational practice.
FDA's guidance explicitly states that computer software assurance principles "can be applied to AI tools if used as part of production or quality systems," making this alignment formal rather than implied.
Implementing CSA for AI in an existing validation program
Labs transitioning to computer software assurance for AI systems should work through three practical steps.
The first is a function-level risk inventory. Map each AI function against its intended use and its consequence of failure. An anomaly-detection function whose output triggers human review before any regulated record is affected carries lower process risk than one that generates values directly in a batch record.
21 CFR Part 11 compliance applies to any function creating or modifying records required by predicate rules, regardless of its CSA risk tier; both frameworks operate simultaneously and independently.
The second is vendor evidence assessment. Under computer software assurance, labs can credit supplier testing, software development lifecycle (SDLC) documentation, and third-party certifications as part of their assurance record. For AI vendors this means requesting training data provenance, model evaluation reports, and change notification policies, rather than recreating validation from scratch.
Vendors who cannot supply this documentation are not ready for a GxP-regulated customer, and that determination is better made at procurement than at inspection.
The third is a model update change control framework. Define upfront which model changes require a formal risk assessment, which require targeted assurance activities, and which can proceed with monitoring only. Document this as part of the system's validation plan so future updates are handled consistently and inspectors can trace the rationale for each decision.
The broader question of evaluating and implementing AI across laboratory workflows involves these same governance decisions; computer software assurance provides the regulatory structure that makes them defensible.
Common questions when transitioning
Does FDA still accept CSV? Yes. Computer system validation remains a compliant approach; computer software assurance is FDA's current recommended framework, not a mandatory replacement.
Labs maintaining strong CSV programs are not out of compliance. They may simply be performing more work than the risk warrants.
Who is responsible for computer software assurance? CSA requires cross-functional input: IT assesses system capabilities and vendor documentation; quality assesses risk and approves the assurance approach; lab operations defines intended use and validates performance against real-world workflows.
No single function owns it alone. The validation plan should document how each stakeholder's contribution is incorporated into the overall assurance record.
What happens to existing validated systems? Existing CSV packages do not need retroactive conversion. Computer software assurance applies going forward to new systems and material changes.
Most labs apply CSA principles to their next validation cycle while maintaining existing CSV packages for systems already in a validated state. This staged transition is consistent with FDA's intent and reduces disruption to ongoing compliance activities.
Computer software assurance and AI: building validation programs that last
Computer software assurance changes how regulated labs should approach AI validation: function-level risk assessment replaces system-level documentation; vendor evidence replaces internally recreated testing where appropriate; and lifecycle monitoring replaces point-in-time validation snapshots. For AI specifically, these are not accommodations: they are the appropriate framework for a technology that updates continuously, behaves probabilistically, and requires ongoing performance monitoring to remain fit for purpose. Labs that build AI validation programs on computer software assurance from the start will produce inspection-ready evidence with less effort and greater relevance to actual system risk.
This content includes text that has been generated with the assistance of AI. For more information, view Lab Manager's AI use policy.
References
U.S. Food and Drug Administration. Computer Software Assurance for Production and Quality Management System Software: Guidance for Industry and FDA Staff. February 3, 2026 (supersedes September 24, 2025 version). Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/computer-software-assurance-production-and-quality-management-system-software
U.S. Food and Drug Administration. General Principles of Software Validation: Final Guidance for Industry and FDA Staff. January 11, 2002. Available at: https://www.fda.gov/media/73141/download
International Society for Pharmaceutical Engineering. GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems, Second Edition. ISPE, 2022.
